Should FDA Grant Accelerated Approval to Duchenne Muscular Dystrophy Gene Therapy?
(MedPage Today) -- On May 12, independent experts narrowly recommended that the FDA grant accelerated approval to Sarepta's new gene therapy, SRP-9001 (delandistrogene moxeparvovec), for the treatment of Duchenne muscular dystrophy (DMD). These...
Source: MedPage Today Neurology - Category: Neurology Source Type: news
More News: Brain | Gene Therapy | Genetics | Grants | Muscular Dystrophy | Neurology | Reflex Sympathetic Dystrophy